Trial Profile
A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
- Indications Carcinoma; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms GeparNuevo
- 09 Aug 2022 Results published in the Annals of Oncology
- 04 Apr 2022 Data of 162 patients was used to validate the results of gene expression, germline variant, and somatic mutation features associated with pathologic response to neoadjuvant durvalumab plus chemotherapy in basal-like triple negative breast cancer ,published in the Clinical Cancer Research
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology